Boryung Pharm concludes supply agreement of KRW 85.4 billion worth finished drugs with Sandoz

Published: 2016-06-22 13:32:53

Updated: 2016-06-22 13:32:53

On the 20^th, Boryung Pharm officially announced the exclusive license and product supply agreement of KRW 85.4 billion to 6 East Asian countries with Sandoz AG, a subsidiary of Novartis Group.

According to Boryung Pharm(CEO Tae-hong Choi) the company established an export agreement of ‘Cilnidipin,’ a calcium channel blocker antihypertensive, with the multinational pharmaceutical company, Novar...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.